These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21971162)

  • 21. Progress toward measles and rubella elimination in Egypt.
    El Sayed N; Kandeel N; Barakat I; Moussa I; Alexander JP; Naouri B; Reef SE
    J Infect Dis; 2011 Jul; 204 Suppl 1():S318-24. PubMed ID: 21666180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MMR vaccine uptake rates: a data validation study.
    Ghebrehewet S; Falconer M; McDonald P; Schlecht B
    Commun Dis Public Health; 2003 Jun; 6(2):144-6. PubMed ID: 12889295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing the uptake of childhood immunisation in rural areas.
    Henderson R; Oates K; MacDonald H; Smith WC; Selvaraj S
    Br J Gen Pract; 2004 Feb; 54(499):114-8. PubMed ID: 14965390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Increasing the immunization rate against measles, mumps, and rubella in medical students at the University of Berne].
    Germann D; Matter L
    Schweiz Med Wochenschr; 1999 Apr; 129(13):499-507. PubMed ID: 10322563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
    Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. General practice factors and MMR vaccine uptake: structure, process and demography.
    Lamden KH; Gemmell I
    J Public Health (Oxf); 2008 Sep; 30(3):251-7. PubMed ID: 18487248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evaluation of measles, mumps and rubella vaccine coverage in 3 year old children in twelve French counties. Time-trends and related factors].
    Rotily M; Guagliardo V; Fontaine D; Garros B; Mayer C; Arrighi J; Woronoff AS; Ledesert B; Lepec R; Chabaud F; Janvrin MP; Baudier F
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):331-41. PubMed ID: 11567200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization coverage and its relationship to preventive health care visits among inner-city children in Baltimore.
    Guyer B; Hughart N; Holt E; Ross A; Stanton B; Keane V; Bonner N; Dwyer DM; Cwi JS
    Pediatrics; 1994 Jul; 94(1):53-8. PubMed ID: 8008538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parental confidence in measles, mumps and rubella vaccine: evidence from vaccine coverage and attitudinal surveys.
    Ramsay ME; Yarwood J; Lewis D; Campbell H; White JM
    Br J Gen Pract; 2002 Nov; 52(484):912-6. PubMed ID: 12434960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium.
    Theeten H; Vandermeulen C; Roelants M; Hoppenbrouwers K; Depoorter AM; Van Damme P
    Acta Paediatr; 2009 Aug; 98(8):1307-12. PubMed ID: 19432835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.